Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Image-related biomarker solutions developer VirtualScopics has signed a $3 million contract with GlaxoSmithKline to collaborate on a large-scale osteoarthritis clinical trial program.
Subscribe to our email newsletter
For this study, VirtualScopics will analyze magnetic resonance imaging (MRI) data on subjects with osteoarthritis, and will be responsible for co-managing the collection of MRI data from sites located throughout North America, Asia and Europe.
According to the company, VirtualScopics is able to integrate in-depth knowledge of image-based biomarkers, expertise in a variety of medical imaging techniques, and proprietary software tools that can precisely assess disease progression after the intervention of a drug or device, with fewer patients and at a lower cost than conventional approaches.
“GlaxoSmithKline is a global leader in drug development, consistently ranking as one of the world’s top five spenders in ethical R&D,” said Bob Klimasewski, president and CEO of VirtualScopics. “Their decision to collaborate with VirtualScopics on a study of this magnitude demonstrates the value placed on our technology and capabilities.”